Skip to content

Study · Randomized controlled trial · n = 20 · 2012

5 results

Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels.

Ha SJ, Kim W, Woo JS, Kim JB, Kim SJ, Kim WS, Kim MK, Cheng XW, Kim KS

Arteriosclerosis, thrombosis, and vascular biology8 Dec 2011Cited by 49 (Europe PMC)

PMID22155457 (opens in a new tab)DOI10.1161/atvbaha.110.222653 (opens in a new tab)PepBankPUB-22155457
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In volunteers, radial artery diameter before ischemia-reperfusion did not differ between exenatide and placebo.

    In plain wordsIn volunteers, radial artery diameter before ischemia-reperfusion did not differ between exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePre-IR radial artery diameter
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Pre-IR radial artery diameter, FMD, and baseline radial artery diameter after IR injury were similar between 2 groups (P=no significant difference).
    2 context sentences
    Summary · context
    In a double-blind, placebo-controlled, crossover design, 20 volunteers were randomly assigned to 2 groups: subcutaneous exenatide (10 μg) or placebo administration.
    Summary · context
    At 30 minutes after the study drug administration, endothelium-dependent flow-mediated dilatation (FMD) of the radial artery was measured before and after IR (15 minutes of ischemia at the level of the brachial artery followed by 15 minutes of reperfusion) injury.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In volunteers, flow-mediated dilatation before ischemia-reperfusion did not differ between exenatide and placebo.

    In plain wordsIn volunteers, artery dilatation before ischemia-reperfusion did not differ between exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePre-IR flow-mediated dilatation
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Pre-IR radial artery diameter, FMD, and baseline radial artery diameter after IR injury were similar between 2 groups (P=no significant difference).
    2 context sentences
    Summary · context
    In a double-blind, placebo-controlled, crossover design, 20 volunteers were randomly assigned to 2 groups: subcutaneous exenatide (10 μg) or placebo administration.
    Summary · context
    At 30 minutes after the study drug administration, endothelium-dependent flow-mediated dilatation (FMD) of the radial artery was measured before and after IR (15 minutes of ischemia at the level of the brachial artery followed by 15 minutes of reperfusion) injury.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In volunteers, baseline radial artery diameter after ischemia-reperfusion did not differ between exenatide and placebo.

    In plain wordsIn volunteers, baseline radial artery diameter after ischemia-reperfusion did not differ between exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBaseline radial artery diameter after IR
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Pre-IR radial artery diameter, FMD, and baseline radial artery diameter after IR injury were similar between 2 groups (P=no significant difference).
    2 context sentences
    Summary · context
    In a double-blind, placebo-controlled, crossover design, 20 volunteers were randomly assigned to 2 groups: subcutaneous exenatide (10 μg) or placebo administration.
    Summary · context
    At 30 minutes after the study drug administration, endothelium-dependent flow-mediated dilatation (FMD) of the radial artery was measured before and after IR (15 minutes of ischemia at the level of the brachial artery followed by 15 minutes of reperfusion) injury.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In volunteers, exenatide prevented ischemia-reperfusion-induced impairment of flow-mediated dilatation versus placebo, with no significant within-exenatide change.

    In plain wordsIn volunteers, exenatide preserved artery dilatation after ischemia-reperfusion compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasePreservation of post-IR flow-mediated dilatation
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    10 μg · subcutaneousAs given in this study (human).

    Measurements

    FMD
    15%
    exenatide before IR
    FMD
    15%
    exenatide after IR

    Source sentences

    Summary
    Exenatide prevented this impairment (FMD before IR: 15.0±7.14%; FMD after IR: 15.0±5.96%, P=no significant difference; P<0.001 compared with placebo).
    2 context sentences
    Summary · context
    In a double-blind, placebo-controlled, crossover design, 20 volunteers were randomly assigned to 2 groups: subcutaneous exenatide (10 μg) or placebo administration.
    Summary · context
    At 30 minutes after the study drug administration, endothelium-dependent flow-mediated dilatation (FMD) of the radial artery was measured before and after IR (15 minutes of ischemia at the level of the brachial artery followed by 15 minutes of reperfusion) injury.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 05HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialMechanism

    In volunteers, glibenclamide pretreatment abolished exenatide's protection of flow-mediated dilatation after ischemia-reperfusion.

    In plain wordsIn volunteers, glibenclamide abolished exenatide's protection of artery dilatation after ischemia-reperfusion compared with exenatide without glibenclamide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlibenclamide blockade of protection
    Study

    n = 7

    Comparator
    Exenatide without glibenclamide pretreatment
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Measurements

    FMD
    12%
    before IR with glibenclamide pretreatment
    FMD
    3.2%
    after IR with glibenclamide pretreatment

    Source sentences

    Summary
    In a separate protocol, this protective effect was completely abolished by pretreatment with glibenclamide (glyburide, 5 mg), a blocker of K(ATP) channels (n=7; FMD before IR: 12.0±2.2%; after IR: 3.2±2.1%, P<0.001).
    2 context sentences
    Summary · context
    In a double-blind, placebo-controlled, crossover design, 20 volunteers were randomly assigned to 2 groups: subcutaneous exenatide (10 μg) or placebo administration.
    Summary · context
    At 30 minutes after the study drug administration, endothelium-dependent flow-mediated dilatation (FMD) of the radial artery was measured before and after IR (15 minutes of ischemia at the level of the brachial artery followed by 15 minutes of reperfusion) injury.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.